Table 1.
Baseline demographics, mean (SD) or number (%)
| Overall | BMI <25 | BMI 25–30 | BMI >30 | P-value | ||||
|---|---|---|---|---|---|---|---|---|
| N = 43 | N = 17 | N = 12 | N = 14 | |||||
| BMI1,* | 28.9 (9.0) | 21.3 | (2.3) | 27.2 | (1.4) | 39.5 | (7.3) | |
| Age (years)* | 52.1 (12.9) | 49.9 | (16.9) | 56.6 | (7.5) | 51.1 | (10.5) | 0.37 |
| Disease duration (years)* | 7.3 (7.8) | 7.4 | (9.6) | 4.0 | (3.8) | 10.1 | (7.2) | 0.14 |
| Female** | 37 (86%) | 17 | (100%) | 8 | (67%) | 12 | (86%) | 0.02 |
| RF2 or CCP3 Positive** | 27 (66%) | 11 | (69%) | 9 | (75%) | 7 | (54%) | 0.55 |
| DMARD (Y) | 40 (93%) | 1 | (6%) | 0 | (0%) | 2 | (14%) | 0.48 |
| Biologics (Y) | 8 (19%) | 2 | (12%) | 2 | (17%) | 4 | (28%) | 0.55 |
| Prednisone (Y) | 7 (16%) | 3 | (18%) | 2 | (17%) | 2 | (14%) | 0.99 |
1Body Mass Index, 2Rheumatoid Factor, 3Cyclic citrullinated peptide, *Mean (SD) and one-way ANOVA, **N (%) and Fisher Exact Test